TNFRSF17 and plasma cell myeloma: Belantamab mafodotin consists of an afucosylated IgG1 monoclonal antibody that specifically targets BCMA expressed on the surface of myeloma cells coupled with a potent cytotoxic agent named monomethyl auristin-F (MMAF).